Before the pandemic, Baxter International ( BAX ) was considered one of the better businesses in the health care space. At the end of 2019, BAX stock traded at about 25x that year's earnings per share, a significant premiumI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail broke ...

Before the pandemic, Baxter International ( BAX ) was considered one of the better businesses in the health care space. At the end of 2019, BAX stock traded at about 25x that year's earnings per share, a significant premiumI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail broke ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https: ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Baxter To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Baxter between February 23, 2022 and July 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional inform ...

CONTACT US HERE:https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form- 2/?id=174900&from=4 CLASS PERIOD: February 23, 2022 to July 30, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Baxter's recently launched product, the Novum LVP, suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-del ...

With a market cap of $9.5 billion, Baxter International Inc. (BAX) is a global healthcare company that specializes in medical products and therapies, with a strong focus on renal care, medication delivery, and pharmaceuticals. The company provides a wide range of healthcare solutions for hospitals, clinics, and home care settings worldwide. Shares of the Deerfield, Illinois-based company have lagged behind the broader market over the past 52 weeks. BAX stock has decreased 48.5% over this time frame, while ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, about the upcoming lead plaintiff deadline of December 15, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which Baxter was aware of but did not adequately address [5] - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Baxter To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Baxter between February 23, 2022 and July 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - ...

Stocks have support after President Trump and President Xi Jinping on Thursday agreed to extend a tariff truce, roll back export controls, and reduce other trade barriers. The US will cut fentanyl-related tariffs on Chinese goods to 10% from 20% and extend a pause on some reciprocal tariffs for an additional year, while China resumes purchases of US soybeans, sorghum, and other farm products. The agreement also includes China pausing controls on rare-earth magnets in exchange for the US rolling back an expa ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]